Newsletter

SINGAPORE: CYBERSECURITY LABELLING SCHEME FOR MEDICAL DEVICES SANDBOX - DECEMBER/JANUARY 2024

SINGAPORE: CYBERSECURITY LABELLING SCHEME FOR MEDICAL DEVICES SANDBOX - DECEMBER/JANUARY 2024

  • 2023-12-26 02:27:39

Following the industrial consultation earlier this year, Cyber Security Agency (CSA) of Singapore is launching Sandbox as a voluntary trial program for Cybersecurity Labelling Scheme for Medical Devices (CLS(MD)). This program started on 20th October 2023 and will be held for 9 months. CSA is inviting medical device manufacturers to participate in Sandbox to have a first-mover advantage in enhancing the security of their products.

The Sandbox allows all parties involved to test out and give feedback on the requirements and application process for the CLS(MD) ahead of the scheme’s launch. Along with the launch of Sandbox program, CSA also published intensive set of regulations related to the requirements and implementation of CLS(MD).

More
QT ANALYSIS: UPDATE IN THE CYBERSECURITY REGULATIONS OF MEDICAL DEVICES IN ASIA (CHINA, JAPAN, SINGAPORE) — AUGUST/SEPTEMBER 2023

QT ANALYSIS: UPDATE IN THE CYBERSECURITY REGULATIONS OF MEDICAL DEVICES IN ASIA (CHINA, JAPAN, SINGAPORE) — AUGUST/SEPTEMBER 2023

  • 2023-08-23 06:27:14

Qualtech highlights the critical role of cybersecurity in safeguarding medical devices and patient well-being, emphasizing the potential risks posed by connectivity and the need for stringent measures to counteract vulnerabilities. We emphasize the collaborative efforts required among medical device stakeholders to establish and maintain robust security standards. This QT analysis revisits a previous cybersecurity article with a focus on recent developments in Japan, China, and Singapore.

More
SINGAPORE: COVID-19 TEST KITS AUTHORIZED FOR PROFESSIONAL AND SELF-USE IN SINGAPORE — AUGUST/SEPTEMBER 2023

SINGAPORE: COVID-19 TEST KITS AUTHORIZED FOR PROFESSIONAL AND SELF-USE IN SINGAPORE — AUGUST/SEPTEMBER 2023

  • 2023-08-23 05:30:31

Effective July 1, 2023, COVID-19 diagnostic tests for professional use and self-test kits that were previously authorized under the Pandemic Special Access Route (PSAR) should now be registered through full-fledged product registration. In addition, validation requirement documents for each product type for professional use only and self-test kits were also issued by HSA.

More
SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

  • 2023-07-21 02:32:25

Singapore's Health Science Authority (HSA) is pleased to announce their status as a recognized Stringent Regulatory Authority (SRA) for Class C and D IVD by WHO. The SRA status means high-risk IVD products registered with HSA might obtain faster evaluation through WHO prequalification assessment, enabling manufacturers accelerated access to global markets.

More
SINGAPORE: Consultation on GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices– June/July 2023

SINGAPORE: Consultation on GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices– June/July 2023

  • 2023-06-28 07:35:36

HSA would like to consult the industry/stakeholders regarding updates and revisions of GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices (R3). The key update includes clarification notes on the classification of control materials and software, also clarifications to the risk classification rules 1-5. The consultation period is open from 2-30 May 2023 through email to HSA.

More
SINGAPORE: HSA Publishes Regulatory Guidelines for Laboratory Developed Tests (LDTs) – January/February 2023

SINGAPORE: HSA Publishes Regulatory Guidelines for Laboratory Developed Tests (LDTs) – January/February 2023

  • 2023-01-19 02:06:31

The Singaporean Health Sciences Authority (HSA) has updated the regulatory guidelines for Laboratory Developed Tests (LDTs) based on the feedback from the stakeholders for the draft that was published for consultation last July 12 - August 12, 2022. The finalized version is coded as GL – 08 R1 with the title of “Regulatory Guidelines for Laboratory Developed Tests (LDTs)”and will be effective on March 1, 2023.

More